Business Wire

Regula Launches Full Support for Digital Travel Credentials in Latest Software Update

15.1.2025 08:00:00 CET | Business Wire | Press release

Share

Regula, a global developer of forensic devices and identity verification solutions, has updated its Regula Document Reader SDK. Now, the software fully supports the new Digital Travel Credential (DTC) format, aligned with the International Civil Aviation Organization (ICAO) standards. This enhancement enables governments, airlines, and border control authorities worldwide to process travel documents with unmatched security, efficiency, and ease—whether on-site or remotely.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250115990355/en/

null

With Regula Document Reader SDK, travelers can create their own digital credentials by extracting a Virtual Component (DTC-VC) from a physical electronic identity document like ePassport. (Graphic: Regula)

The DTC is a secure digital solution that streamlines travel experiences. It consolidates key personal information into a single virtual document that travelers can store on their mobile devices or upload to their digital wallets and share whenever needed. The main goal of the DTC is to facilitate clearance procedures during travel and ensure that people are eligible to enter their destination before they board a flight.

The ICAO has defined three types of DTC, each offering varying levels of convenience and security for travelers.

  • DTC Type 1 allows travelers to create their own digital credentials by extracting a Virtual Component (DTC-VC) from a physical electronic identity document, stored on their personal device. However, travelers must still carry the original document for identity verification.
  • DTC Type 2, issued by authorities, combines a cryptographically linked Virtual Component (DTC-VC) and a Physical Component (DTC-PC). This format adds an extra layer of security while maintaining a connection to the physical document.
  • DTC Type 3 represents the future of travel identification: a fully digital document issued directly by authorities. Unlike the other types, it eliminates the need for a physical ID, streamlining identity verification for a completely digital experience.

Now, with Regula Document Reader SDK, users can create and reprocess DTC-VC from ePassports, and verify it by passing DTC-VC data as input. Also, support for handling DTC-PC has been introduced. The updated Regula Document Reader SDK can:

  • read the document’s RFID chip with a smartphone or passport reader and create DTC-VC;
  • recognize, read, and verify DTC-VC with a smartphone, passport reader, or server;
  • read DTC-PC with a smartphone or passport reader, parse its data, and verify it.

The updated Regula Document Reader SDK is equipped with advanced features that fully support DTC implementation.

  • Trustworthy NFC verification. First and foremost, it provides trusted server-side NFC verification of the ID so it ensures accurate and trustworthy DTC-VC creation. Since all the data from the chip can be verified on a secure server, there is no need to question the reliability of the checks performed by a mobile device (which is prone to manipulation). Such an approach ensures that the virtual component of a traveler’s document is secure and taken from an authentic ID.
  • Compliance with ICAO guidelines and technical reports. Regula Document Reader SDK not only verifies DTCs but also guarantees that each DTC fully complies with ICAO guidelines and technical reports. This makes Regula’s solution an indispensable tool for airlines and governments so they can be confident in the validity of travelers’ DTCs.
  • Future-ready technology. In addition to supporting DTC-VC, Regula’s technology is fully compatible with handling DTC-PC. Looking further ahead, Regula is ready to process DTC Type 3, a digital passport that is expected in the next several years.

To facilitate the fast and smooth global application of DTCs, Regula Document Reader SDK relies on the most comprehensive identity document template database, which is owned and maintained by Regula. Currently, it contains more than 14,000 ID templates from 251 countries and territories, and it’s constantly growing.

Regula Document Reader SDK is designed for easy integration into third-party applications, allowing clients to incorporate this advanced DTC-ready technology seamlessly into their existing systems. With customizable options, businesses can adapt the solution to meet their unique operational requirements while providing end users with a secure, streamlined digital experience.

“We see that the world is rapidly moving to embrace digital IDs. According to the Forrester Consulting study commissioned by Regula earlier in 2024, nearly half of businesses around the world, 42%, are actively integrating digital IDs into their systems. For the Aviation sector, this rate is even higher: 50%. By ensuring full DTC support in the latest update of Regula Document Reader SDK, we are helping our clients to smoothly transition to the future of travel, where secure, digital-first solutions redefine the passenger experience,” says Ihar Kliashchou, Chief Technology Officer at Regula.

To learn more about the capabilities of the updated Regula Document Reader SDK, read the release documentation on Regula’s website.

About Regula

Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the most comprehensive library of document templates in the world, we create breakthrough technologies for document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification. Learn more at www.regulaforensics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250115990355/en/

null

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye